Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Add shares to your
quickpicks to
display them here!

Puretech (PRTC)

Price 230.50p on 02-06-2023 at 16:48:55
Change 13.50p 6.22%
Buy 229.00p
Sell 227.50p
Buy / Sell PRTC Shares
Last Trade: Unknown 1,271.00 at 220.612p
Day's Volume: 170,670
Last Close: 230.50p
Open: 225.00p
Day's Range 219.50p - 230.50p
52wk Range: 145.80p - 300.00p
Market Capitalisation: £640m
VWAP: 227.25208p
Shares in Issue: 278m

Recent Trades History Puretech (PRTC)

Buy/Sell Volume Trade Prc Trade Type Trade Time
Unknown* 1,271 220.612p Ordinary
Currency Conversion
16:48:41 - 02-Jun-23
Unknown* 2,938 223.856p Ordinary
Currency Conversion
OTC Trade
16:21:49 - 02-Jun-23
Unknown* 14,844 224.209p Ordinary
Currency Conversion
OTC Trade
16:03:16 - 02-Jun-23
Unknown* 4,472 228.50p Ordinary
OTC Trade
15:45:00 - 02-Jun-23
Unknown* 4,472 228.50p Ordinary
OTC Trade
15:45:00 - 02-Jun-23
Buy* 67,693 230.50p Suspected BUY Trade
15:35:01 - 02-Jun-23
Sell* 1,114 228.50p Automatic Execution
15:28:43 - 02-Jun-23
Sell* 158 228.50p Automatic Execution
15:28:43 - 02-Jun-23
Unknown* 4,000 228.50p Ordinary
Currency Conversion
15:27:08 - 02-Jun-23
Buy* 134 228.50p Automatic Execution
15:26:31 - 02-Jun-23

Share Price History for Puretech

Time period:
Date Open High Low Close Volume

Share News for Puretech

PureTech's Vedanta Biosciences receives US FDA fast track designation

9th May 2023 11:13

(Alliance News) - PureTech Health PLC on Tuesday said its founded entity, Vedanta Biosciences, has been granted fast track designation from the US Food & Drug Administration for its bacterial consortium candidate, VE303, for the prevention of recurrent Clostridioides difficile infection. Read More

IN BRIEF: PureTech notes Akili's results for EndeavorRx ADHD trial

4th May 2023 11:46

PureTech Health PLC - Boston-based biotechnology company - Says its founded entity, Akili, announced clinical trial for video game-based therapy, EndeavorRx, showed improvement in attention and quality of life for people with attention deficit hyperactivity disorder. Notes attention improved in more than 80% of adults with ADHD, while over a third of participants "no longer exhibited an attention deficit following treatment." Read More

LONDON BROKER RATINGS: HSBC raises Rightmove to 'buy' from 'hold'

2nd May 2023 09:34

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning: Read More

PureTech Health yearly loss widens but remains optimistic

28th Apr 2023 11:13

(Alliance News) - PureTech Health PLC on Friday said its loss widened in 2022 and revenue declined, though it hailed an "exceptional" year and expects further success in 2023. Read More

TRADING UPDATES: Eagle Eye signs new John Lewis deal, Neometals update

25th Apr 2023 18:33

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on xxxday and not separately reported by Alliance News: Read More

FTSE 100 Latest

Login to your account

Forgot Password?

Not Registered